Jeffrey R. Marks

46.5k citations

222 papers · 16.1k indexed · 3 hit papers · h-index 66

Impact in

Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
Oncology top 0.2%
- Cancer-related Molecular Pathways

Papers in

Reproductive Medicine 42
- Ovarian cancer diagnosis and treatment 42
Cancer Research 69
- Breast Cancer Treatment Studies 24
- Cancer Genomics and Diagnostics 22

Co-authors: Andrew Berchuck J. Dirk Iglehart Joseph R. Nevins John A. Olson Holly K. Dressman Mike West Andrew M. Davidoff Johnathan M. Lancaster
Journals: Cancer Epidemiology Biomarkers & Prevention (12 papers)Cancer Research (12 papers)Gynecologic Oncology (10 papers)Journal of Clinical Oncology (9 papers)Cancer (8 papers)
Partner nations: United States United Kingdom China

In The Last Decade

Jeffrey R. Marks

214 papers receiving 15.8k citations

Hit Papers

align trajectories log scale

Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression 2008 · 646 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2008 Journal of Clinical Oncology
2005 Nature
2001 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Jeffrey R. Marks

Since Specialization

Citations

This map shows the geographic impact of Jeffrey R. Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey R. Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey R. Marks more than expected).

Fields of papers citing papers by Jeffrey R. Marks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey R. Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey R. Marks. The network helps show where Jeffrey R. Marks may publish in the future.

Co-authors

The 25 scholars most cited alongside Jeffrey R. Marks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jeffrey R. Marks Line = papers co-authored together Jeffrey R. Marks links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Single-Cell Expression Analysis of Ductal Carcinoma In Situ Identifies Complex Genotypic–Phenotypic Relationships Altering Epithelial Composition Cancer Research ·Xiaodi Qin, Siri H. Strand, Marissa R. Lee, Aashrith Saraswathibhatla, David G.P. van IJzendoorn, Chunfang Zhu, Sujay Vennam, Sushama Varma, Allison Hall, Rachel E. Factor, Lorraine King, Lunden Simpson, Xiaoke Luo, Graham A. Colditz, Shu Jiang, Ovijit Chaudhuri, E. Shelley Hwang, Jeffrey R. Marks, Kouros Owzar, Robert B. West	2025	1
2	Molecular Subtypes of High-Grade Serous Ovarian Cancer across Racial Groups and Gene Expression Platforms Cancer Epidemiology Biomarkers & Prevention ·Natalie R. Davidson, Mollie E. Barnard, Ariel A. Hippen, Amy Campbell, Courtney E. Johnson, Gregory P. Way, Brian K. Dalley, Andrew Berchuck, Lucas A. Salas, Lauren C. Peres, Jeffrey R. Marks, Joellen M. Schildkraut, Casey S. Greene, Jennifer A. Doherty	2024	4
3	Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features Radiology ·Rui Hou, Lars J. Grimm, Maciej A. Mazurowski, Jeffrey R. Marks, Lorraine King, Carlo C. Maley, Thomas Lynch, Marja van Oirsouw, Keith D. Rogers, Nicholas Stone, Matthew Wallis, Jonas Teuwen, Jelle Wesseling, E. Shelley Hwang, Joseph Y. Lo	2022	25
4	A new method to accurately identify single nucleotide variants using small FFPE breast samples Briefings in Bioinformatics ·Angelo Fortunato, Diego Mallo, Shawn Rupp, Lorraine King, Timothy Hardman, Joseph Y. Lo, Allison Hall, Jeffrey R. Marks, E. Shelley Hwang, Carlo C. Maley	2021	4
5	DNA methylation markers predict recurrence-free interval in triple-negative breast cancer npj Breast Cancer ·Mary Jo Fackler, Soonweng Cho, Leslie Cope, Edward Gabrielson, Kala Visvanathan, Kathleen Wilsbach, Danielle Meir-Levi, Charles F. Lynch, Jeffrey R. Marks, Joseph Geradts, Meredith M. Regan, Giuseppe Viale, Antonio C. Wolff, Saraswati Sukumar, Christopher B. Umbricht	2020	21
6	LncRNAs-directed PTEN enzymatic switch governs epithelial–mesenchymal transition Cell Research ·Qingsong Hu, Chunlai Li, Shouyu Wang, Yajuan Li, Bo Wen, Yanyan Zhang, Ke Liang, Jun Yao, Youqiong Ye, Heidi Hsiao, Tina K. Nguyen, Peter K. Park, Sergey D. Egranov, David H. Hawke, Jeffrey R. Marks, Leng Han, Mien‐Chie Hung, Bing Zhang, Chunru Lin, Liuqing Yang	2019	39
7	Glycosylation of KEAP 1 links nutrient sensing to redox stress signaling The EMBO Journal ·Po‐Han Chen, Timothy J. Smith, Jianli Wu, Priscila F. Siesser, Brittany J. Bisnett, Farhan Mohammad Khan, Maxwell Hogue, Erik J. Soderblom, Flora Tang, Jeffrey R. Marks, Michael B. Major, Benjamin M. Swarts, Michael Boyce, Jen‐Tsan Chi	2017	85
8	Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions Cancer Epidemiology Biomarkers & Prevention ·Daniel L. Adams, Diane K. Adams, R. Katherine Alpaugh, Massimo Cristofanilli, Stuart S. Martin, Saranya Chumsri, Cha-Mei Tang, Jeffrey R. Marks	2016	63
9	Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma Gynecologic Oncology ·Sharareh Siamakpour‐Reihani, Kouros Owzar, Chen Jiang, T.B. Turner, Yiwen Deng, Sarah M. Bean, Janet K. Horton, Andrew Berchuck, Jeffrey R. Marks, Mark W. Dewhirst, Angeles Alvarez Secord	2015	29
10	Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease Cancer Epidemiology Biomarkers & Prevention ·Jeffrey R. Marks, Karen S. Anderson, Paul F. Engstrom, Andrew K. Godwin, Laura J. Esserman, Gary Longton, Edwin S. Iversen, Anu Mathew, Christos Patriotis, Margaret S. Pepe	2014	13
11	Genome-wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence Cancer Research ·Mary Jo Fackler, Christopher B. Umbricht, Danielle Williams, Pedram Argani, Leigh-Ann Cruz, Vanessa F. Merino, Wei Wen Teo, Zhe Zhang, Peng Huang, Kala Visvananthan, Jeffrey R. Marks, Stephen P. Ethier, Joe W. Gray, Antonio C. Wolff, Leslie Cope, Saraswati Sukumar	2011	159
12	Plasma Biomarker Profiles Differ Depending on Breast Cancer Subtype but RANTES Is Consistently Increased Cancer Epidemiology Biomarkers & Prevention ·Rachel Gonzalez, Don S. Daly, Ruimin Tan, Jeffrey R. Marks, Richard C. Zangar	2011	35
13	An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicty and Enhanced Therapeutic Efficacy without Oncogenicity Clinical Cancer Research ·Zachary C. Hartman, Jun-Ping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Peplinski, Dong‐Wan Kim, Wenle Xia, Neil L. Spector, Jeffrey R. Marks, William T. Barry, Amy Hobeika, Gayathri R. Devi, Andrea Amalfitano, Michael A. Morse, H. Kim Lyerly, Timothy M. Clay	2010	21
14	Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome Clinical Cancer Research ·Andrew Berchuck, Edwin S. Iversen, Jingqin Luo, Jennifer Clarke, Hisani N. Horne, Douglas A. Levine, Jeff Boyd, Miguel A. Alonso, Angeles Alvarez Secord, Marcus Q. Bernardini, Jason C. Barnett, Todd Boren, Susan K. Murphy, Holly K. Dressman, Jeffrey R. Marks, Johnathan M. Lancaster	2009	60
15	Inactivation of the MAL Gene in Breast Cancer Is a Common Event That Predicts Benefit from Adjuvant Chemotherapy Molecular Cancer Research ·Hisani N. Horne, Paula S. Lee, Susan K. Murphy, Miguel A. Alonso, John A. Olson, Jeffrey R. Marks	2009	38
16	Isogenic Normal Basal and Luminal Mammary Epithelial Isolated by a Novel Method Show a Differential Response to Ionizing Radiation Cancer Research ·Gudrun Hüper, Jeffrey R. Marks	2007	31
17	Combined cDNA Array Comparative Genomic Hybridization and Serial Analysis of Gene Expression Analysis of Breast Tumor Progression Cancer Research ·Jun Yao, Stanislawa Weremowicz, Bin Feng, Robert Gentleman, Jeffrey R. Marks, Rebecca Gelman, Cameron Brennan, Kornélia Polyák	2006	133
18	Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy Clinical Cancer Research ·Holly K. Dressman, Christopher Hans, Andrea H. Bild, John A. Olson, Eric L. Rosen, P. Kelly Marcom, Vlayka Liotcheva, Ellen L. Jones, Željko Vujašković, Jeffrey R. Marks, Mark W. Dewhirst, Mike West, Joseph R. Nevins, Kimberly Blackwell	2006	121
19	Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays American Journal of Obstetrics and Gynecology ·Andrew Berchuck, Edwin S. Iversen, Johnathan M. Lancaster, Holly K. Dressman, Mike West, Joseph R. Nevins, Jeffrey R. Marks	2004	80
20	BRCA2 Monoclonal Antibodies React with Differentiating Epithelium PubMed ·Lisa K. Gilliam, Edward K. Lobenhofer, Paula K. Greer, Richard M. Scearce, Frank D. Cirisano, Jeffrey R. Marks, Laura P. Hale	2002	1

About Jeffrey R. Marks

Jeffrey R. Marks is a scholar working on Reproductive Medicine, Cancer Research, Oncology, Molecular Biology and Genetics, having authored 222 papers that have together received 16.1k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (42 papers), Cancer-related Molecular Pathways (29 papers), Breast Cancer Treatment Studies (24 papers), Cancer Genomics and Diagnostics (22 papers), BRCA gene mutations in cancer (19 papers), Radiomics and Machine Learning in Medical Imaging (18 papers), HER2/EGFR in Cancer Research (17 papers) and AI in cancer detection (16 papers). The work is most often cited by research in Cancer Research (4.6k citations), Oncology (5.6k citations), Reproductive Medicine (1.7k citations), Molecular Biology (9.3k citations) and Genetics (2.5k citations). Jeffrey R. Marks has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Andrew Berchuck, J. Dirk Iglehart, Joseph R. Nevins, John A. Olson, Holly K. Dressman, Mike West, Andrew M. Davidoff, Johnathan M. Lancaster, Saraswati Sukumar and Robert C. Bast. Their work appears in journals such as Cancer Epidemiology Biomarkers & Prevention, Cancer Research, Gynecologic Oncology, Journal of Clinical Oncology and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact